These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33783225)

  • 1. Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
    Van de Poël A; Toledo-Sherman L; Breccia P; Cachope R; Bate JR; Angulo-Herrera I; Wishart G; Matthews KL; Martin SL; Peacock M; Barnard A; Cox HC; Jones G; McAllister G; Vater H; Esmieu W; Clissold C; Lamers M; Leonard P; Jarvis RE; Blackaby W; Eznarriaga M; Lazari O; Yates D; Rose M; Jang SW; Muñoz-Sanjuan I; Dominguez C
    J Med Chem; 2021 Apr; 64(8):5018-5036. PubMed ID: 33783225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.
    Toledo-Sherman L; Breccia P; Cachope R; Bate JR; Angulo-Herrera I; Wishart G; Matthews KL; Martin SL; Cox HC; McAllister G; Penrose SD; Vater H; Esmieu W; Van de Poël A; Van de Bospoort R; Strijbosch A; Lamers M; Leonard P; Jarvis RE; Blackaby W; Barnes K; Eznarriaga M; Dowler S; Smith GD; Fischer DF; Lazari O; Yates D; Rose M; Jang SW; Muñoz-Sanjuan I; Dominguez C
    J Med Chem; 2019 Mar; 62(6):2988-3008. PubMed ID: 30840447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
    Pasquier B; El-Ahmad Y; Filoche-Rommé B; Dureuil C; Fassy F; Abecassis PY; Mathieu M; Bertrand T; Benard T; Barrière C; El Batti S; Letallec JP; Sonnefraud V; Brollo M; Delbarre L; Loyau V; Pilorge F; Bertin L; Richepin P; Arigon J; Labrosse JR; Clément J; Durand F; Combet R; Perraut P; Leroy V; Gay F; Lefrançois D; Bretin F; Marquette JP; Michot N; Caron A; Castell C; Schio L; McCort G; Goulaouic H; Garcia-Echeverria C; Ronan B
    J Med Chem; 2015 Jan; 58(1):376-400. PubMed ID: 25402320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.
    Lu XH; Mattis VB; Wang N; Al-Ramahi I; van den Berg N; Fratantoni SA; Waldvogel H; Greiner E; Osmand A; Elzein K; Xiao J; Dijkstra S; de Pril R; Vinters HV; Faull R; Signer E; Kwak S; Marugan JJ; Botas J; Fischer DF; Svendsen CN; Munoz-Sanjuan I; Yang XW
    Sci Transl Med; 2014 Dec; 6(268):268ra178. PubMed ID: 25540325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
    Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.
    Henley ZA; Amour A; Barton N; Bantscheff M; Bergamini G; Bertrand SM; Convery M; Down K; Dümpelfeld B; Edwards CD; Grandi P; Gore PM; Keeling S; Livia S; Mallett D; Maxwell A; Price M; Rau C; Reinhard FBM; Rowedder J; Rowland P; Taylor JA; Thomas DA; Hessel EM; Hamblin JN
    J Med Chem; 2020 Jan; 63(2):638-655. PubMed ID: 31855425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.
    Tidball AM; Bryan MR; Uhouse MA; Kumar KK; Aboud AA; Feist JE; Ess KC; Neely MD; Aschner M; Bowman AB
    Hum Mol Genet; 2015 Apr; 24(7):1929-44. PubMed ID: 25489053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress of ATM inhibitors: Opportunities and challenges.
    Du S; Liang Q; Shi J
    Eur J Med Chem; 2024 Nov; 277():116781. PubMed ID: 39173286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
    Min J; Guo K; Suryadevara PK; Zhu F; Holbrook G; Chen Y; Feau C; Young BM; Lemoff A; Connelly MC; Kastan MB; Guy RK
    J Med Chem; 2016 Jan; 59(2):559-77. PubMed ID: 26632965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.
    Dong Q; Dougan DR; Gong X; Halkowycz P; Jin B; Kanouni T; O'Connell SM; Scorah N; Shi L; Wallace MB; Zhou F
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1315-9. PubMed ID: 21310613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
    Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
    J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recently emerging signaling landscape of ataxia-telangiectasia mutated (ATM) kinase.
    Farooqi AA; Attar R; Arslan BA; Romero MA; ul Haq MF; Qadir MI
    Asian Pac J Cancer Prev; 2014; 15(16):6485-8. PubMed ID: 25169474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Autophagy Specific Lipid Kinase VPS34 for Cancer Treatment: An Integrative Repurposing Strategy.
    Murali P; Verma K; Rungrotmongkol T; Thangavelu P; Karuppasamy R
    Protein J; 2021 Feb; 40(1):41-53. PubMed ID: 33400087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors.
    Shaik A; Bhakuni R; Kirubakaran S
    Molecules; 2018 Apr; 23(5):. PubMed ID: 29695073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
    Pike KG; Barlaam B; Cadogan E; Campbell A; Chen Y; Colclough N; Davies NL; de-Almeida C; Degorce SL; Didelot M; Dishington A; Ducray R; Durant ST; Hassall LA; Holmes J; Hughes GD; MacFaul PA; Mulholland KR; McGuire TM; Ouvry G; Pass M; Robb G; Stratton N; Wang Z; Wilson J; Zhai B; Zhao K; Al-Huniti N
    J Med Chem; 2018 May; 61(9):3823-3841. PubMed ID: 29683659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization.
    Siu T; Kumarasinghe SE; Altman MD; Katcher M; Northrup A; White C; Rosenstein C; Mathur A; Xu L; Chan G; Bachman E; Bouthillette M; Dinsmore CJ; Marshall CG; Young JR
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1466-71. PubMed ID: 24582987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
    Degorce SL; Barlaam B; Cadogan E; Dishington A; Ducray R; Glossop SC; Hassall LA; Lach F; Lau A; McGuire TM; Nowak T; Ouvry G; Pike KG; Thomason AG
    J Med Chem; 2016 Jul; 59(13):6281-92. PubMed ID: 27259031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ULK1-mediated phosphorylation of ATG14 promotes autophagy and is impaired in Huntington's disease models.
    Wold MS; Lim J; Lachance V; Deng Z; Yue Z
    Mol Neurodegener; 2016 Dec; 11(1):76. PubMed ID: 27938392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors.
    Hu DX; Patel S; Chen H; Wang S; Staben ST; Dimitrova YN; Wallweber HA; Lee JY; Chan GKY; Sneeringer CJ; Prangley MS; Moffat JG; Wu KC; Schutt LK; Salphati L; Pang J; McNamara E; Huang H; Chen Y; Wang Y; Zhao W; Lim J; Murthy A; Siu M
    J Med Chem; 2022 Sep; 65(17):11500-11512. PubMed ID: 34779204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Characterization of VPS34 Lipid Kinase Inhibition by Small Molecules.
    Fassy F; Dureuil C; Lamberton A; Mathieu M; Michot N; Ronan B; Pasquier B
    Methods Enzymol; 2017; 587():447-464. PubMed ID: 28253972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.